WEBULL
News
CRMD
7.48
+0.61%
0.05
CorMedix Inc. to Present at Major Healthcare Investor Conferences
Reuters · 3h ago
Cormedix: Rezzayo and DefenCath Prophylaxis Upside Underscores Buy Rating and $13 DCF-Based Target
TipRanks · 1d ago
Cormedix: Steady Near-Term Base with High-Impact Label Expansion Catalysts Justifying a Buy Rating
TipRanks · 1d ago
Analyst Expectations For Cormedix's Future
Benzinga · 1d ago
CorMedix Is Maintained at Buy by D. Boral Capital
Dow Jones · 1d ago
CorMedix Price Target Maintained With a $14.00/Share by D. Boral Capital
Dow Jones · 1d ago
Cormedix (CRMD) Receives a Buy from RBC Capital
TipRanks · 1d ago
D. Boral Capital Maintains Buy on Cormedix, Maintains $14 Price Target
Benzinga · 1d ago
Weekly Report: what happened at CRMD last week (0202-0206)?
Weekly Report · 3d ago
Catalyst Watch: Crypto swings, FedEx investor event, and Super Bowl bets
Seeking Alpha · 5d ago
Analysts’ Top Healthcare Picks: Cormedix (CRMD), CG Oncology, Inc. (CGON)
TipRanks · 02/04 13:03
CorMedix Shares Rise After $75M Buyback Authorization
Dow Jones · 02/02 15:32
CorMedix sets $75M stock buyback plan
Seeking Alpha · 02/02 14:06
CorMedix Announces $75 Mln Share Buyback Program
NASDAQ · 02/02 13:55
CorMedix Therapeutics Announces $75M Buyback Plan
Benzinga · 02/02 13:38
CorMedix board authorizes share repurchase program of up to $75M
TipRanks · 02/02 13:35
*CorMedix Therapeutics Announces Share-Repurchase Program of Up to $75M
Dow Jones · 02/02 13:31
CORMEDIX INC - TO BEGIN SHARE REPURCHASE IN Q1 2026
Reuters · 02/02 13:30
Weekly Report: what happened at CRMD last week (0126-0130)?
Weekly Report · 02/02 09:32
CorMedix Hosts Analyst Day to Showcase Pipeline and Growth Drivers
Reuters · 01/29 13:31
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.